Bone Marrow–Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence‐Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein–Interferon‐β Feedback Loop
- 4 May 2017
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatology
- Vol. 69 (8) , 1623-1635
Abstract
Objective: Bone marrow–derived mesenchymal stem cells (BM‐MSCs) create a special microenvironment for hematopoiesis and immunity and display robust immunomodulatory properties that are impaired in systemic lupus erythematosus (SLE). This study was undertaken to identify the mechanisms of defects in human SLE BM‐MSCs.Methods: Patients fulfilling SLE classification criteria and healthy controls (n = 6 per group) were recruited according to an institutional review board–approved protocol. BM‐MSCs were isolated with low‐density Ficoll‐Hypaque, verified by flow cytometry, and studied using immunocytochemistry, real‐time polymerase chain reaction, Western blotting, comet assay, β‐galactosidase assay, and RNA interference.Results: SLE BM‐MSCs had a senescent phenotype characterized by a reduced proliferation rate, increased production of reactive oxygen species, increased DNA damage and repair, increased expression of p53 and p16, which block the cell cycle, and altered cytokine production (increased proinflammatory cytokine production and decreased immunomodulatory cytokine production). Moreover, SLE BM‐MSCs had a 5‐fold increase in interferon‐β (IFNβ) levels (P < 0.05 versus healthy controls) and increased IFNβ‐induced messenger RNAs (mRNAs), including mRNA for the intracellular nucleic acid–sensing adaptor protein mitochondrial antiviral signaling protein (MAVS), whose expression was highly correlated with IFNβ levels (r > 0.9, P < 0.01). Since MAVS is known to induce IFNβ production, we hypothesized that there is a positive feedback loop between MAVS and IFNβ. Notably, silencing of MAVS markedly decreased IFNβ, p53, and p16 protein levels and expression of mRNAs for proinflammatory cytokines.Conclusion: This study demonstrates a novel pathway for elevated IFNβ signaling in SLE that is not dependent on stimulation by immune complexes but rather is cell intrinsic and critically mediated by IFNβ and MAVS, implicating new pathways as potential therapeutic targets.Keywords
Funding Information
- Alliance for Lupus Research
- University of Rochester
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1UH2‐AR‐067690)
- Lupus Foundation of America
This publication has 49 references indexed in Scilit:
- The Hallmarks of AgingCell, 2013
- Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic SignalingImmunity, 2012
- A loss‐of‐function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patientsEMBO Molecular Medicine, 2011
- Mitochondrial Antiviral Signaling Protein Plays a Major Role in Induction of the Fish Innate Immune Response against RNA and DNA VirusesJournal of Virology, 2009
- RNA Polymerase III Detects Cytosolic DNA and Induces Type I Interferons through the RIG-I PathwayCell, 2009
- Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretionNature Cell Biology, 2009
- A Modular Analysis Framework for Blood Genomics Studies: Application to Systemic Lupus ErythematosusImmunity, 2008
- Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosusNature Genetics, 2007
- Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3Cell, 2005
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992